The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tutt, A. L.
Right arrow Articles by Glennie, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tutt, A. L.
Right arrow Articles by Glennie, M. J.
The Journal of Immunology, 2002, 168: 2720-2728.
Copyright © 2002 by The American Association of Immunologists

T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody1

Alison L. Tutt, Lyn O’Brien, Akmal Hussain, Graham R. Crowther, Ruth R. French and Martin J. Glennie2

Tenovus Research Laboratory, Cancer Sciences Division, University School of Medicine, Southampton General Hospital, Southampton, United Kingdom

In this study we demonstrate that treatment with anti-CD40 mAb eradicates a range of mouse lymphomas (BCL1, A31, A20, and EL4), but only when used against i.v. tumor doses in excess of 107 cells. Only partial protection was seen against smaller tumor loads. We saw no evidence that anti-CD40 mAb changed the phenotype of the lymphomas or inhibited their growth in the initial period following treatment, but it did result in a rapid expansion of cytotoxic CD8+ cells that was able to clear the neoplastic disease and provide long-term protection against tumor rechallenge. The CTL responses were blocked by mAb against a range of coreceptors and cytokines, including CD8, B7-1, B7-2, LFA-1, and IFN-{gamma}, but not CD4 or CTLA-4, indicating the presence of a conventional cellular Th1 response. Furthermore, we found evidence of cross-recognition between lymphomas (BCL1 and A20) as measured by cytotoxicity and IFN-{gamma} responses in vitro and using tumor rechallenge experiments, suggesting common target Ags. Finally, although anti-CD40 was shown to stimulate NK cell killing, we could find no role for these cells in controlling tumor growth. These data underline the ability of anti-CD40 mAb to potentiate CTL responses and the potency of cellular immunity in eradicating large quantities of syngeneic tumor.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
Q.-L. Wu, I. N. Buhtoiarov, P. M. Sondel, A. L. Rakhmilevich, and E. A. Ranheim
Tumoricidal Effects of Activated Macrophages in a Mouse Model of Chronic Lymphocytic Leukemia
J. Immunol., June 1, 2009; 182(11): 6771 - 6778.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Kim, K. Park, H. J. Kim, J. Kim, H.-A Kim, D. Jung, H. J. Kim, H.-J. Choi, S.-Y. Choi, K. W. Seo, et al.
Breaking of CD8+ T Cell Tolerance through In Vivo Ligation of CD40 Results in Inhibition of Chronic Graft-versus-Host Disease and Complete Donor Cell Engraftment
J. Immunol., November 15, 2008; 181(10): 7380 - 7389.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L-L. Chiang, J. A. Ledermann, E. Aitkens, E. Benjamin, D. R. Katz, and B. M. Chain
Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor
Clin. Cancer Res., August 1, 2008; 14(15): 4898 - 4907.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. R. French, V. Y. Taraban, G. R. Crowther, T. F. Rowley, J. C. Gray, P. W. Johnson, A. L. Tutt, A. Al-Shamkhani, and M. J. Glennie
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation
Blood, June 1, 2007; 109(11): 4810 - 4815.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Illidge
Anti-CD40: Janus or gatekeeper?
Blood, October 15, 2005; 106(8): 2595 - 2596.
[Full Text] [PDF]

Home page
 BloodHome page
M.-G. de Goer de Herve, D. Durali, T.-A. Tran, G. Maigne, F. Simonetta, P. Leclerc, J.-F. Delfraissy, and Y. Taoufik
Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: the Janus face of anti-CD40
Blood, October 15, 2005; 106(8): 2806 - 2814.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Honeychurch, M. J. Glennie, and T. M. Illidge
Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody-Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells
Cancer Res., August 15, 2005; 65(16): 7493 - 7501.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Li, A. C. Grover, E. J. Donald, A. Carr, J. Yu, J. Whitfield, M. Nelson, N. Takeshita, and A. E. Chang
Simultaneous Targeting of CD3 on T Cells and CD40 on B or Dendritic Cells Augments the Antitumor Reactivity of Tumor-Primed Lymph Node Cells
J. Immunol., August 1, 2005; 175(3): 1424 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. N. Buhtoiarov, H. Lum, G. Berke, D. M. Paulnock, P. M. Sondel, and A. L. Rakhmilevich
CD40 Ligation Activates Murine Macrophages via an IFN-{gamma}-Dependent Mechanism Resulting in Tumor Cell Destruction In Vitro
J. Immunol., May 15, 2005; 174(10): 6013 - 6022.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Hill, S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al.
Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis
J. Immunol., January 1, 2005; 174(1): 41 - 50.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Gendelman, N. Halligan, R. Komorowski, B. Logan, W. J. Murphy, B. R. Blazar, K. A. Pritchard Jr, and W. R. Drobyski
Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration
Blood, January 1, 2005; 105(1): 428 - 431.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. F. H. M. Boonman, G. J. D. van Mierlo, M. F. Fransen, K. L. M. C. Franken, R. Offringa, C. J. M. Melief, M. J. Jager, and R. E. M. Toes
Intraocular Tumor Antigen Drains Specifically to Submandibular Lymph Nodes, Resulting in an Abortive Cytotoxic T Cell Reaction
J. Immunol., February 1, 2004; 172(3): 1567 - 1574.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Honeychurch, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma
Blood, August 15, 2003; 102(4): 1449 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Dechant, G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. J. van de Winkel, and T. Valerius
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing
Blood, December 15, 2002; 100(13): 4574 - 4580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.